



## Financial Tear Sheet

### Corporate Profile

Depomed is a specialty pharmaceutical company focused on pain and other central nervous system conditions. We currently market FDA-approved products, NUCYNTA<sup>®</sup> ER, NUCYNTA<sup>®</sup>, Gralise<sup>®</sup>, Cambia<sup>®</sup>, Lazanda<sup>®</sup> and Zipsor<sup>®</sup>. We actively seek to expand our product portfolio by identifying product acquisition targets that fit within our pain and neurology portfolio, have lengthy periods of exclusivity and have untapped market potential. Depomed also has successfully developed and licensed its proprietary oral drug-delivery technology, Acuform<sup>®</sup>, that allows for the targeted, extended release of pharmaceutical compounds into the upper gastrointestinal tract. Depomed has licensed Acuform technology to six pharmaceutical partners, and the technology is currently being used in four marketed drugs, including NUCYNTA ER and Gralise.

The following are abbreviated descriptions of Depomed's products:

**NUCYNTA<sup>®</sup> ER** (tapentadol) extended release tablets indicated, CII for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate and in adult patients who have neuropathic pain associated with diabetic peripheral neuropathy (DPN) that is severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate;

**NUCYNTA<sup>®</sup>** (tapentadol) an immediate release version of tapentadol, is indicated for the management of moderate to severe acute pain in adults;

**Gralise<sup>®</sup>** (gabapentin), a once-daily product for the management of postherpetic neuralgia,

**Cambia<sup>®</sup>** (diclofenac potassium for oral solution) for acute treatment of migraine attacks with or without aura in adults 18 years of age or older,

**Lazanda<sup>®</sup>** (fentanyl) nasal spray CII for the management of breakthrough pain in cancer patients, 18 years of age and older, who are already receiving and who are tolerant to regular opioid therapy for their underlying persistent cancer pain, and

**Zipsor<sup>®</sup>** (diclofenac potassium) liquid filled capsules, a product for the treatment of mild to moderate acute pain in adults.

See Important Safety Information for [Gralise](#) and the black box warnings for [NUCYNTA ER](#), [NUCYNTA](#), [Cambia](#), [Lazanda](#) and [Zipsor](#).

### Stock Performance

#### DEPO (COMMON STOCK)

Exchange NASDAQ CM (US Dollar)

Price **\$10.79**

Change (%) **▲ 0.28 (2.66%)**

Volume 898,429

52 Week Low \$9.38

Market Cap \$679,360,120

Rolling EPS -1.54

PE Ratio N/A

Shares Outstanding 62,962,013



## Recent Headlines

07/13/17  
Depomed Announces Intent to Effect a Debt Refinancing

05/22/17  
Depomed Announces Corporate Governance Updates

05/16/17  
Depomed to Present at the UBS Global Healthcare Conference

## Upcoming Events

08/15/17 2:00 p.m. PT  
Depomed 2017 Annual Shareholder Meeting

## Ownership Summary

### TOP HOLDERS

	Shares Held	% O/S	Share Change	Filing Date
BlackRock Institutional Trust Company, N.A.	8,362,807	13.3	612,419	03/31/17
Senvest Management, LLC	5,400,005	8.6	220,000	03/31/17
Starboard Value LP	5,295,270	8.4	0	07/17/17
The Vanguard Group, Inc.	4,791,200	7.6	609,722	03/31/17
Oak Ridge Investments, LLC	2,382,409	3.8	-374,029	03/31/17
State Street Global Advisors (US)	2,374,915	3.8	130,760	03/31/17
Invesco PowerShares Capital Management LLC	2,083,017	3.3	-31,795	03/31/17
Naya Management LLP	1,954,916	3.1	-523,754	03/31/17
Litespeed Management LLC	1,833,698	2.9	650,746	03/31/17
Dimensional Fund Advisors, L.P.	1,242,450	2.0	-93,615	03/31/17

Powered By **EDGAR**Online

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.

Minimum 20 minutes delayed